Barclays raises target for Qiagen stock to USD 55
Published on 10/14/2026 at 11:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Barclays moved its Qiagen target from USD 40.00 to USD 55.00 on October 6, 2026.
- Adjusted earnings per share reached USD 0.62 in the second quarter of 2026 against USD 0.60 consensus.
- Qiagen stock trades at EUR 40.84 at 11:07 a.m. CEST at Lang & Schwarz on October 14, 2026, minus 0.38 percent versus the Xetra close of October 13, 2026.
Qiagen (ISIN NL0015002SN0) was trading at EUR 40.84 at Lang & Schwarz on October 14, 2026 at 11:07 a.m. CEST, down 0.38 percent versus the Xetra close of EUR 41.00 on October 13, 2026. The latest analyst action came from Barclays, which upgraded Qiagen from Equal Weight to Overweight and raised its price target from USD 40.00 to USD 55.00 on October 6, 2026, according to Markets Insider.
Three events shape the setup
On October 2, 2026, a report said takeover discussions involving Qiagen and at least one potential buyer may have advanced, while the stock rose 7.30 percent in the cited market reaction, according to Citybiz. No buyer or transaction was identified in that report.
On October 6, 2026, Qiagen announced two artificial intelligence platforms for bioinformatics and drug discovery. The products build on QIAGEN Digital Insights tools used by 150,000 users, according to Finanznachrichten.
What does the target reset imply?
Barclays' target increase equals a 37.50 percent rise from USD 40.00 to USD 55.00. The bank cited conservative 2027 growth estimates for the tools sector, valuation support and the possibility of private equity interest, according to Markets Insider. The target is denominated in US dollars and is therefore not directly comparable with the euro quote from Lang & Schwarz.
Qiagen reported USD 535.04 million of revenue and adjusted earnings per share of USD 0.62 in the second quarter of 2026, against analyst estimates of USD 527.50 million and USD 0.60, respectively, according to MarketBeat. Net income in the quarter was USD 103.40 million, while operating cash flow reached USD 200.69 million.
Results date brings the next test
MarketBeat lists November 3, 2026, as the estimated date for Qiagen's third-quarter results and November 4, 2026, at 9:30 a.m. ET for the conference call, with consensus revenue of USD 535.62 million and earnings per share of USD 0.6210, according to MarketBeat. That forecast compares with USD 532.58 million of revenue and USD 0.6421 of earnings per share in the year-earlier quarter.
Qiagen stock stays below its Xetra close
At Lang & Schwarz, Qiagen stock was trading at EUR 40.84 on October 14, 2026 at 11:07 a.m. CEST, minus 0.38 percent versus the Xetra close of October 13, 2026 at EUR 41.00. The quote was in the regular Xetra trading phase.
The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.
Qiagen stock facts
- Company: Qiagen N.V.
- ISIN: NL0015002SN0
- Ticker: QGEN
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 11:07 a.m. CEST): EUR 40.84
- Change versus Xetra close: minus 0.38 percent
- Xetra close (October 13, 2026): EUR 41.00
- Market capitalization: USD 9.4 billion (as of October 13, 2026)
- 52-week range: USD 32.53-57.82 (as of October 13, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Index membership: DAX
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
